General information

Piridoxilate, an equimolar mixture of glyoxylic acid and pyridoxine, is marketed in a few countries (for example France) for peripheral arterial occlusive disease and functional venous disorders [ ], including vascular ulcers [ , ]. The supposed rationale is that glyoxylate has a membrane protective action and pyridoxine should prevent oxidation of glyoxylic acid to oxalic acid (but see below under Urinary tract ).

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here